Compugen's COM701 Trial Progresses as AstraZeneca Expands Rilvegostomig Program
Event summary
- Compugen's MAIA-ovarian trial for COM701 remains on track, with median progression-free survival data expected by Q1 2027.
- AstraZeneca presented new overall survival data for rilvegostomig at ASCO 2026, showing a median of 16.8 months in biliary tract cancer.
- Gilead-partnered GS-0321 Phase 1 trial continues to progress as planned.
- Compugen reports $125.3 million in cash, with runway expected into 2029.
The big picture
Compugen's progress in its immuno-oncology pipeline, particularly with COM701 and rilvegostomig, reflects the growing importance of AI/ML-powered drug discovery in cancer immunotherapy. The strategic partnerships with AstraZeneca and Gilead underscore the industry's shift toward collaborative development models to address high unmet needs in oncology.
What we're watching
- Clinical Milestones
- Whether COM701's interim analysis in Q1 2027 will demonstrate clear prolongation of PFS, potentially informing a registration path.
- Pipeline Advancement
- The pace at which AstraZeneca advances rilvegostomig across its 12 ongoing Phase 3 trials, including the recently initiated urothelial carcinoma trial.
- Financial Sustainability
- How Compugen's cash runway into 2029 will support its operating plans and potential future collaborations.
Related topics